Respiri developing Next Generation AirSonea device
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Last Thursday’s announcement by Respiri (ASX: RSH) regarding the development of a next-generation breath sensor to replace the AirSonea 2013 model triggered a positive response from the market with its shares increasing 10% to an intraday high of 4.3 cents.
Of course it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
As a market leader in the development of innovative devices and mobile health apps, which improve the management of chronic and costly respiratory disorders such as asthma and COPD, the development of a new device will assist the company in maintaining a competitive edge in that industry segment.
Consequently, this news could spark positive near to medium-term share price momentum after the company appeared to be sold down in June, largely due to tax loss selling.
Release of market ready device assisted by record of gaining regulatory approvals
Explaining the company’s strategy management said, “Whilst there have been significant technology changes to the 2013 AirSonea breath sensor device that received regulatory approval for sales in Europe, it is imperative that Respiri integrates the latest technology components to maintain our competitive edge in a rapidly evolving technological environment”.
Management stressed the importance of the company’s successful history of regulatory approvals as setting it apart from most companies in the medical technology and biotech industries that are still undergoing various trials.
The development of a market ready device, which is expected to be poised for release in six months, could provide a significant boost to second-half revenues in fiscal 2018.
Partnership negotiations are already in progress, but management said that it was difficult to indicate exactly when agreements were likely to be struck.
However, the company did note that as previously advised, it had received a written commercial-in-confidence proposal to establish a partnership vehicle in China, and subsequent variations have been extended to include global considerations.
Given that the potential deal structure is complex, involving at least six parties and requiring detailed negotiations over an extended period this initiative is likely to take a number of months.
Market data indicates continued demand for asthma and COPD devices
RSH highlighted that market research continued to strongly indicate that there was an unmet need for an over-the-counter, smart symptom monitoring product that supports patient compliance with asthma plans and complement drug delivery products such as prescription smart inhalers.
The over-the-counter breath sensor captures and transmits breath sounds to RSH’s state-of-the-art software technology platform where the group’s clinically proven proprietary technology detects and measures wheeze.
The latest generation app allows users to set preventer medication reminders, log symptoms, allergic triggers and reliever medication doses. This provides a complete digital asthma history securely stored in the cloud.
RSH is in a strong position to fund development of the new product with cash at bank of $2.2 million as at July 14, 2017.
The company’s forecasts cash flow includes research and development tax incentives of $600,000 over the next six months. Depending on the timing of research and development expenditures and incentives, management is forecasting net cash burn of approximately $100,000 per month.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.